CSTL FY 2023 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

FY 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$220M+60.4% YoY

Gross Profit

$175M79.5% margin

Operating Income

-$68M-30.9% margin

Net Income

-$57M-26.1% margin

EPS (Diluted)

$-2.14

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$19M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$453M

Total Liabilities

$62M

Stockholders' Equity

$391M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$220M	$137M	+60.4%
Gross Profit	$175M	$105M	+66.4%
Operating Income	-$68M	-$73M	+6.7%
Net Income	-$57M	-$67M	+14.4%